Oslo

• Plasma cell targeting in ME/CFS Recruiting
  2024-520094-13-00 4 2025-06-11 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
• Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting
  2024-513122-27-00 5 2025-06-10 Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal … Recruiting
  2024-512302-25-00 5 2025-06-06 Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
• The Nordic Chronic Migraine Trial of CGRP monoclonal antibody and onabotulinumtoxin A dual therapy – a randomized-controlled double-blind tr … Recruiting
  2024-517981-40-00 5 2025-06-06 Chronic Migraine
• A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's … Recruiting
  2023-509391-42-00 11 2025-06-02 Chron's Disease
• Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 … Recruiting
  2023-508196-36-00 4 2025-05-27 Follicular lymphoma
• A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting
  2024-517147-31-00 9 2025-05-23 Tumours, Gynecological
• Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa … Recruiting
  2024-516030-35-00 5 2025-04-30 Multiple myeloma
• A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido … Recruiting
  2024-515279-37-00 5 2025-04-17 Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
• Anticoagulation with apixaban in venous malformations Recruiting
  2024-511930-11-00 4 2025-04-15 Venous malformation
• Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE. Recruiting
  2024-513779-42-02 4 2025-03-27 Cancer
• Thrombolysis in Factor Xa-inhibitors Trial (SIFT) Recruiting
  2023-509907-34-01 5 2025-03-10 acute ischemic stroke
• Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting
  2024-513443-93-00 4 2025-03-10 Recurrent Meningioma without local treatment options (Surgery or Radio
• eHealth Based treatment of AdolescenT obesiTy with Low energy diet and sEmaglutide (eBATTLE Obesity) Recruiting
  2023-506289-29-00 6 2025-02-28 Obesity
• A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum Recruiting
  2024-514306-31-00 5 2025-02-13 Pyoderma gangrenosum
• A pilot study of enalapril in venous malformations Recruiting
  2023-510076-31-00 4 2025-01-30 Venous malformation
• Water absorption in brain of hydrocephalus Recruiting
  2024-519933-53-00 5 2025-01-29 Adult hydrocephalus
• Intrathecal MRI Contrast for Assessment of CSF Transport Recruiting
  2024-519936-18-00 6 2025-01-29 CSF disorders
• A pilot study for optimizing meropenem administration in the intensive care unit – short six times vs. prolonged three times courses daily Recruiting
  2024-520030-30-00 5 2025-01-23 Serious infection requiring broad-spectrum antibiotic
• A Phase II trial of ginisortamab in participants with metastatic pancreatic ductal adenocarcinoma Recruiting
  2024-514129-43-00 4 2025-01-15 Metastatic pancreatic ductal adenocarcinoma
• Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated gl … Recruiting
  2023-506998-35-00 5 2025-01-08 Glioblastoma
• A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k … Recruiting
  2023-510150-17-00 4 2024-12-11 Active, refractory systemic lupus erythematosus (SLE), and active, re
• Prospective, multicenter, randomized, open-label, parallel-group controlled phase 3 study of tacrolimus minimization in kidney transplant re … Recruiting
  2022-502624-44-00 5 2024-12-10 kidney transplantation
• A study to test long-term treatment with brigimadlin in people with solid tumours who took part in a previous study with this medicine Recruiting
  2024-514177-21-00 4 2024-12-02 Solid tumours

Showing 145–168 of 508 trials